Innovative Products The following innovative products have obtained the registration certificate of regulatory authorities for the first time in the industry based on the technology platform, and are open to the..

Original from: Diasorin ¡¤ Revenues: € 876 million, +4% ¡°as reported¡± compared to September 2023; +7% ex covid (+8% at constant perimeter of Consolidation1) ¡¤ Adjusted2 ebitda3: € 2..

Siemens Healthineers AG today announces its results for the fourth quarter of fiscal year 2024 ended September 30, 2024, and the full fiscal year 2024.

Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2024.

On November 8, 2024, Roche Diagnostics enhanced the company's long term commitment to China's local healthcare industry, to ultimately benefit patients in China and beyond, with the opening of its new Roche Diagnostics Head Office in China.

Original from: BD BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2024 fourth quarter and full year which ended Septemb..

Original from: QuidelOrtho Third Quarter 2024 Results and Recent Developments (all comparisons are to the prior year period) ¡¤ Reported revenue was $727 million - Recurring revenue1 w..

As of 31 October, 2024, all mainland-listed Chinese IVD companies have released their third-quarter financial reports. This summary provides insights into 50 main IVD enterprises and 20 IVD-related enterprises for ref..

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2024.

Orginal from: Qiagen ¡¤ Q3 2024: Net sales of $502 million (+5% actual rates, +6% constant exchange rates, CER); diluted EPS of $0.44 and adjusted diluted EPS of $0.57 ¡¤ Net sales of $502 millio..

CareDx, Inc. (Nasdaq: CDNA) ¨C today announced financial results for the third quarter ended September 30, 2024.

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Meningitis/Encephalitis Panel for clinical use.

Mindary Q3 Report: Operating Income Reaches ¥29.48 Billion Mindary has released its Q3 2024 results, revealing strong performance in the first three quarters of the year. The company ..

Original from: Revvity ¡¤ Revenue of $684 million; 2% reported growth; 2% organic growth ¡¤ GAAP EPS of $0.77; Adjusted EPS from continuing operations of $1.28 ¡¤ Raises full year 2024 adjust..

Original from: Illumina ¡¤ Core Illumina revenue of $1.1 billion for Q3 2024, down 2% from Q3 2023 and on a constant currency basis ¡¤ Core Illumina GAAP operating margin of 68.6% and non-GAAP oper..